Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04803786 · ClinicalTrials.gov registry record
A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy
A clinical trial, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- 110
- Enrollment target
NCT04803786 is a clinical trial that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 110 participants.
The verdict
NCT04803786 has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- 110 participants
- Enrollment target
Study Summary
The rationale for the patient-centric, prospective, observational, non-interventional study design of JZP258-402 is to evaluate the transition experience of participants with narcolepsy treated with oxybate and to examine the impact of transitioning from Xyrem to Xywav in a real-world setting.
Interventions
- DRUG Transition from Xyrem to Xywav
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2021-04-09 |
| Est. Completion | 2022-02-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04803786
The ClinicalTrials.gov registry entry for NCT04803786 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Transition from Xyrem to Xywav is the first listed.
NCT04803786 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04803786 about?
NCT04803786 is a clinical study titled "A Patient-Centric, Prospective, Observational, Non-Interventional Switch Study of XYWAV in Narcolepsy". The rationale for the patient-centric, prospective, observational, non-interventional study design of JZP258-402 is to evaluate the transition experience of participants with narcolepsy treated with oxybate and to examine the impact of transitioning from Xyrem to Xywav in a real-world setting.
What is the current status of trial NCT04803786?
This trial is currently completed. The enrollment target is 110 participants. The study started on 2021-04-09. Estimated completion is 2022-02-24.
What interventions are being tested in trial NCT04803786?
The interventions under investigation include: Transition from Xyrem to Xywav (DRUG).
Who is sponsoring clinical trial NCT04803786?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.